Compare Charles River Laboratories Intl. Inc (CRL) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Philip Morris International Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $232.14 (market cap $11.14B), while Philip Morris International Inc. trades at $176.63 (market cap $274.23B). The key difference: Philip Morris International Inc. is far larger — about 24.6× Charles River Laboratories Intl. Inc's market cap, and Philip Morris International Inc. pays a 3.34% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | PM | |
|---|---|---|
Market Cap | $11.14B | $274.23B |
Sector | Health | Consumer Staples |
52-Week High | $233.60 | $191.86 |
52-Week Low | $145.57 | $144.33 |
Enterprise Value | $14.00B | $320.73B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Philip Morris International (PM) trades at $180.19, down 0.79% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $194.00. The company reported strong Q1 2026 EPS of $1.96, beating expectations, and maintains robust profitability with a 26.74% net income margin. Recent news includes a $500 million impairment charge in Q2 2026 and CFO succession plans, while cash flow trends show stable operations.
The stock presents a favorable risk-reward profile with upside to analyst targets, driven by earnings beats and brand strength, though risks include currency volatility, regulatory pressures, and consumer spending constraints highlighted in recent Reuters and WSJ reports. Long-term investors may find value in its dividend yield and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
